摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[2-(二甲基氨基)乙基]-1-哌嗪甲醛 | 22764-09-6

中文名称
4-[2-(二甲基氨基)乙基]-1-哌嗪甲醛
中文别名
——
英文名称
1-(2-dimethylamino-ethyl)-4-formyl-piperazine
英文别名
4-[2-(Dimethylamino)ethyl]piperazine-1-carbaldehyde
4-[2-(二甲基氨基)乙基]-1-哌嗪甲醛化学式
CAS
22764-09-6
化学式
C9H19N3O
mdl
MFCD16302497
分子量
185.269
InChiKey
DDKUREMPQDNBOJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    26.8
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933599090

文献信息

  • JAK INHIBITOR
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP2108642A1
    公开(公告)日:2009-10-14
    A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.
    一种JAK抑制剂,其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同,每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物,或类似物;而 R2和R3可以相同也可以不同,每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
  • [EN] SUBSTITUTED PYRAZOLOPYRIDINAMINES<br/>[FR] PYRAZOLOPYRIDINAMINES SUBSTITUÉES
    申请人:BAYER PHARMA AG
    公开号:WO2017081003A1
    公开(公告)日:2017-05-18
    The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)所述的取代吡唑吡啶胺化合物,以及制备该化合物的方法,用于制备该化合物的中间化合物,包含该化合物的药物组合物和配方,以及利用该化合物制造用于治疗或预防疾病的药物组合物,特别是治疗过度增殖、血管生成障碍、炎症性疾病或与炎症性疼痛相关的疾病,作为唯一药物或与其他活性成分组合使用。
  • Selected Benzofuran Derivatives
    申请人:Greiveldinger-Poenaru Sorana
    公开号:US20080108610A1
    公开(公告)日:2008-05-08
    The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds, and especially their use as anti-infectives.
    本发明涉及新的苯并呋喃衍生物及其在制备药物组成物中作为活性成分的用途。本发明还涉及相关方面,包括制备该化合物的过程、含有其中一种或多种化合物的药物组成物,尤其是它们作为抗感染剂的用途。
  • THIENOPYRIMIDINES
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20150133425A1
    公开(公告)日:2015-05-14
    The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)所描述和定义的取代噻唑嘧啶化合物,以及制备该化合物的方法,用于制备该化合物的中间体化合物,包含该化合物的制药组合物和药物组合物,以及使用该化合物制造用于治疗或预防疾病的制药组合物,特别是用作唯一药剂或与其他活性成分组合使用,治疗或预防过度增殖和/或血管生成障碍的疾病。
  • TRIFLUOROMETHYLPYRROLOINDOLE CARBOXYLIC ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
    申请人:KYORIN PHARMACEUTICAL CO., LTD.
    公开号:EP0656360A1
    公开(公告)日:1995-06-07
    Trifluoromethylpyrroloindole carboxylic ester derivatives represented by general formulae (1) and (2) having an antitumor activity, optically active isomers thereof, and pharmacologically acceptable salts thereof, wherein R represents lower alkyl; R¹ represents an α-amino acid residue, etc.; R² represents hydrogen, a hydroxyl-protecting group, etc.; and Y represents halogen, arylsulfonyloxy, etc.
    通式(1)和(2)代表的具有抗肿瘤活性的三氟甲基吡咯吲哚羧酸酯衍生物、其光学活性异构体及其药理上可接受的盐,其中R代表低级烷基;R¹代表α-氨基酸残基等;R²代表氢、羟基保护基等;Y代表卤素、芳基磺酰氧基等。
查看更多